Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome

Bone Marrow Transplantation volume 56, pages 883–889 (2021)Cite this article

Subjects

Abstract

We report the outcome of 68 patients with advanced peripheral T-cell lymphoma receiving transplantation from haploidentical or from conventional donors. The 4-year OS, PFS, 2-year cumulative incidence of relapse and 2-year GRFS was 75%, 70%, 21%, and 51%, respectively. Survival was not affected by donor type. The 2-year NRM was 9%, lower after related or haploidentical donor (21% vs 0% vs 7%; p = 0.06). Grade 2–4 aGVHD cumulative incidence was significantly different after transplantation from haploidentical vs matched sibling vs unrelated donor, and (24% vs 35% vs 58%, p = 0.024). The familial donor cohort was compared to the unrelated cohort. Familial donor induced less grade 2–4 aGVHD, with a trend to less grade 3–4 aGVHD or moderate-severe cGVHD. The OS and PFS were not different, while the relapse risk and NRM were reduced. Allo-SCT is highly effective in T-cell lymphoma, with low NRM and low relapse rate. The incidence of aGVHD was lower after haploidentical transplantation. Related donor may challenge unrelated transplant reducing the risk of relapse and NRM.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Cumulative incidence of GVHD.
Fig. 2: Survival for the entire population.
Fig. 3: Non-relapse mortality by donor type.

Similar content being viewed by others

References

  1. Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood. 2011;117:6756–67.

    Article  CAS  Google Scholar 

  2. Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, et al. Upfront VIP-reinforced –ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of randomized phase III trial GOLEAMS-LTP95. Br J Haematol. 2010;151:159–66.

    Article  Google Scholar 

  3. D’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–9.

    Article  Google Scholar 

  4. Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem cell transplantation as first line therapy in peripheral T cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27:106–13.

    Article  CAS  Google Scholar 

  5. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, et al. The survival outcome of patients with relapsed/refractory peripheral T cell lymphoma not otherwised specified and angioimmunoblastic T cell lymphoma. Br J Haematol. 2017;176:750–8.

    Article  CAS  Google Scholar 

  6. Mak V, Hamm J, Chhanabbai M, SheinKier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970–6.

    Article  CAS  Google Scholar 

  7. Ellin F, Landstrom J, Jekerman M, Relander T. Real world data on prognostic factors and treatment in peripheral T cell lymphomas: a study the Swedish Lymphoma Registry. Blood. 2014;124:1570–7.

    Article  CAS  Google Scholar 

  8. Broccoli A, Argnani L, Zinzani PL. Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease. Cancer Treat Rev. 2017;60:120–9.

    Article  CAS  Google Scholar 

  9. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, et al. Graft –versus lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie cellulaire. J Clin Oncol. 2008;26:2264–71.

    Article  Google Scholar 

  10. Jacobsen ED, Kim HT, Cutler V, Ho VT, Koreth J, Fisher DC, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol. 2011;22:1608–13.

    Article  CAS  Google Scholar 

  11. Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T cell lymphomas: long term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia. 2012;26:520–6.

    Article  CAS  Google Scholar 

  12. Kim SM, Yoon SS, Suzuky R, Matsuno Y, Hy HG, Yhoshida T, et al. Comparison of outcome between autologous and allogeneic hematopoietc stem cell transplantation for peripheral T-cell lymphoma with central review of pathology. Leukemia. 2013;27:1394–440.

    Article  CAS  Google Scholar 

  13. Loirat M, Chevallier P, Leux C, Moreau A, Bossard C, Guillaume T, et al. Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell Lymphoma: an intention-to-treat analysis from a single center. Ann Oncol. 2015;26:386–92.

    Article  CAS  Google Scholar 

  14. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641–50.

    Article  CAS  Google Scholar 

  15. Burroughs LM, O’Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transpl. 2008;14:1279–87.

    Article  Google Scholar 

  16. Martínez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A, et al. Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for hodgkin lymphoma: a registry study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. J Clin Oncol. 2017;35:3425–32.

    Article  Google Scholar 

  17. Castagna L, Bramanti S, Devillier R, Sarina B, Crocchiolo R, Furst S, et al. Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. Bone Marrow Transpl. 2017;52:683–8.

    Article  CAS  Google Scholar 

  18. Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127:938–47.

    Article  CAS  Google Scholar 

  19. Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus hla-matched sibling donors: a center for international blood and marrow transplant research analysis. J Clin Oncol. 2016;34:3141–9.

    Article  CAS  Google Scholar 

  20. Dietrich S, Finel H, Martinez C, Tischer J, Blaise D, Chevallier P, et al. Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation. Leukemia. 2016;30:2086–9.

    Article  CAS  Google Scholar 

  21. Dreger P, Sureda A, Ahn KW, Eapen M, Litovich C, Finel H, et al. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Adv. 2019;3:360–9.

    Article  CAS  Google Scholar 

  22. Gauthier J, Castagna L, Garnier F, Guillaume T, Socié G, Maury S, et al. Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transpl. 2017;52:689–96.

    Article  CAS  Google Scholar 

  23. Kanakry JA, Kasamon YL, Gocke CD, Tsai HL, Davis-Sproul J, Ghosh N, et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transpl. 2013;19:602–6.

    Article  CAS  Google Scholar 

  24. Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma- a LWP-EBMT study. Br J Haematol. 2020;188:745–56.

    Article  CAS  Google Scholar 

  25. Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL, et al. Prospective validation of the predictive power of hematopoietic cell transplantation comorbidity index: a Center for International Blood and Marrow Transplant Research Study. Biol Bone Marrow Transplant. 2015;21:1479–87.

    Article  Google Scholar 

  26. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825–8.

    CAS  Google Scholar 

  27. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389–401.

    Article  Google Scholar 

  28. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol. 2008;26:2264–71.

    Article  Google Scholar 

  29. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091–101.

    Article  CAS  Google Scholar 

  30. Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013;31:3100–9.

    Article  Google Scholar 

  31. Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2009;27:3951–8.

    Article  Google Scholar 

  32. Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia. 2012;26:520–6.

    Article  CAS  Google Scholar 

  33. Zain J, Palmer JM, Delioukina M, Thomas S, Tsai NC, Nademanee A, et al. Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. Leuk Lymphoma. 2011;52:1463–73.

    Article  Google Scholar 

  34. Delioukina M, Zain J, Palmer JM, Tsai N, Thomas S, Forman S. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transpl. 2012;47:65–72.

    Article  CAS  Google Scholar 

  35. Czajczynska A, Günther A, Repp R, Humpe A, Schub N, Raff T, et al. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin’s lymphoma. Biol Blood Marrow Transpl. 2013;19:1632–7.

    Article  CAS  Google Scholar 

  36. Wulf G, Hasenkamp J, Jung W, Wilhelm C, Held G, Nickelsen M, et al. Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease. Bone Marrow Transpl. 2019;54:877–84.

    Article  CAS  Google Scholar 

  37. Debals-Gonthier M, Siani C, Faucher C, Touzani R, Lemarié-Basset C, Chabannon C, et al. Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years. Bone Marrow Transpl. 2018;53:1096–104.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Humanitas Clinical and Research Center, IRCCS, via Manzoni 56, 20089, Rozzano, Milan, Italy

    Luca Castagna, Stefania Bramanti, Jacopo Mariotti, Chiara De Philippis, Barbara Sarina, Carmelo Carlo-Stella & Armando Santoro

  2. Haematology Department, Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, France

    Thomas Pagliardini, Jean Marc Schiano de Colella, Catalina Montes de Oca, Reda Bouabdallah, Sabine Fürst, Angela Granata, Samia Harbi, Faezeh Legrand, Valerio Maisano, Pierre Jean Weiller, Didier Blaise & Raynier Devillier

  3. Centre for Clinical Investigation in Biotherapy, Institut Paoli-Calmettes, Aix-Marseille University, INSERM CBT 1409, Marseille, France

    Christian Chabannon

  4. Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy

    Carmelo Carlo-Stella & Armando Santoro

Authors
  1. Luca Castagna
    View author publications

    Search author on:PubMed Google Scholar

  2. Thomas Pagliardini
    View author publications

    Search author on:PubMed Google Scholar

  3. Stefania Bramanti
    View author publications

    Search author on:PubMed Google Scholar

  4. Jean Marc Schiano de Colella
    View author publications

    Search author on:PubMed Google Scholar

  5. Catalina Montes de Oca
    View author publications

    Search author on:PubMed Google Scholar

  6. Reda Bouabdallah
    View author publications

    Search author on:PubMed Google Scholar

  7. Jacopo Mariotti
    View author publications

    Search author on:PubMed Google Scholar

  8. Sabine Fürst
    View author publications

    Search author on:PubMed Google Scholar

  9. Angela Granata
    View author publications

    Search author on:PubMed Google Scholar

  10. Chiara De Philippis
    View author publications

    Search author on:PubMed Google Scholar

  11. Samia Harbi
    View author publications

    Search author on:PubMed Google Scholar

  12. Barbara Sarina
    View author publications

    Search author on:PubMed Google Scholar

  13. Faezeh Legrand
    View author publications

    Search author on:PubMed Google Scholar

  14. Valerio Maisano
    View author publications

    Search author on:PubMed Google Scholar

  15. Pierre Jean Weiller
    View author publications

    Search author on:PubMed Google Scholar

  16. Christian Chabannon
    View author publications

    Search author on:PubMed Google Scholar

  17. Carmelo Carlo-Stella
    View author publications

    Search author on:PubMed Google Scholar

  18. Armando Santoro
    View author publications

    Search author on:PubMed Google Scholar

  19. Didier Blaise
    View author publications

    Search author on:PubMed Google Scholar

  20. Raynier Devillier
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Luca Castagna.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Castagna, L., Pagliardini, T., Bramanti, S. et al. Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome. Bone Marrow Transplant 56, 883–889 (2021). https://doi.org/10.1038/s41409-020-01133-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41409-020-01133-5

This article is cited by

Search

Advanced search

Quick links